By All patients in the Phase I / II clinical trial of glofitamab had Diffuse Large B-Cell Lymphoma (DLBCL) and their cancer had relapsed or was no longer responding to conventional treatments, including CAR T-cell therapy.
Potent results from a new immune treatment seen in patients with hard-to-treat blood cancers
Comments